Boehringer Ingelheim says new studies underline efficacy of lung disease drug
Boehringer Ingelheim said late-stage trials for its drug to treat chronic lung disease reinstate its efficacy and safety profile.
The company said its Ofev (nintedanib) slowed disease progression in Phase III trials for idiopathic pulmonary fibrosis (IPF).
In addition to slowing of disease progression the drug also reduced lung function decline, the company said in a statement.
Imre Noth, director of the interstitial lung disease program at the University of Chicago, said: “Ongoing analyses of the Phase III Inpulsis trials along with real-world data provide additional support for the safety and efficacy of treatment with Ofev. As slowing disease progression is an important treatment goal, these data provide support for the benefit to IPF patients regardless of disease severity.”
IPF is a debilitating and fatal lung disease with high mortality, affecting as many as 3 million people worldwide. Progression of IPF is variable and unpredictable, and over time the lung function of an IPF patient gradually and irreversibly declines. IPF causes permanent scarring or fibrosis of the lung, difficulty breathing and decreases the amount of oxygen the lungs can supply to major organs of the body.
Eli Lilly and Boehringer Ingelheim have announced that the US Food and Drug Administration (FDA) …
US clinical stage biotherapeutics company Bellerophon Therapeutics has announced that the last patient has completed …
German pharmaceutical company Boehringer Ingelheim (BI) and cell programming and biosecurity platform builder Ginkgo Bioworks …